Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Breathing Intervention for Cardiac Anxiety

Conditions:   Atrial Fibrillation;   Implantable Cardioverter Defibrillator
Intervention:   Behavioral: Breathing exercise
Sponsors:   Laureate Institute for Brain Research, Inc.;   University of Arizona
Recruiting - verified September 2016

Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.

Condition:   Atrial Fibrillation
Intervention:   Drug: aliskiren
Sponsor:   Mika Lehto
Recruiting - verified September 2016

Non-vitamin K Oral Anticoagulants in Cardioversion

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Helsinki University Central Hospital;   University of Turku
Completed - verified September 2016

Comparison of the Ganglionated Plexi Activity in Patients With Different Forms of Atrial Fibrillation Guided by SUMO Technology

Condition:   Atrial Fibrillation
Interventions:   Device: Cardiac CT;   Procedure: Ablation Procedure;   Device: D-SPECT
Sponsors:   Meshalkin Research Institute of Pathology of Circulation;   Spectrum Dynamics
Recruiting - verified September 2016

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)

Condition:   Non Valvular Atrial Fibrillation (nv AF)
Interventions:   Drug: Non-exposed group;   Drug: Exposed group
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified September 2016

Sleep Apnea and Atrial Fibrillation Recurrence

Conditions:   Sleep Apnea Syndrome;   Atrial Fibrillation
Intervention:   Other: Intervention group
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting - verified August 2016

Comparison of Recurrence of Atrial Fibrillation 90 Days Post Cryoballoon Ablation With and Without Anti-Arrhythmic Drugs

Condition:   Atrial Fibrillation
Intervention:   Other: No AAD post Ablation.
Sponsors:   Palmetto Health;   Medtronic
Not yet recruiting - verified September 2016

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Conditions:   Coronary Artery Bypass Grafting;   Postoperative Atrial Fibrilation;   Stroke;   Systemic Embolism;   Deep Venous Thrombosis
Interventions:   Drug: Apixaban;   Drug: Warfarin
Sponsors:   Sanford Health;   Bristol-Myers Squibb
Recruiting - verified September 2016

Catheter Ablation Therapy for Persistent Atrial Fibrillation

Condition:   Persistent Atrial Fibrillation
Intervention:   Procedure: Additional LAAW linear ablation
Sponsors:   China National Center for Cardiovascular Diseases;   Beijing Hospital;   First Affiliated Hospital, Sun Yat-Sen University;   Tianjin Medical University General Hospital;   Wuhan Asia Heart Hospital;   The First Affiliated Hospital of Kunming Medical College
Recruiting - verified September 2016

A Digital Non-interventional Atrial Fibrillation (AF) Screening Study With Commercial Pulse Detection Systems

Condition:   Atrial Fibrillation
Interventions:   Device: 12-point-ECG;   Device: Polar V800;   Device: 360° eMotion FAROS SET + Belt;   Device: Adidas Micoach smart run;   Device: TomTom Runner Cardio;   Device: TomTom Runner Cardio HRM
Sponsor:   Bayer
Not yet recruiting - verified September 2016

Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure

Conditions:   Catheter Ablation;   Rate Control;   Heart Failure;   Atrial Fibrillation
Intervention:  
Sponsor:   Nanjing Medical University
Recruiting - verified September 2016

Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified September 2016

Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Patient Convenience Study- NIS RELATE

Condition:   Atrial Fibrillation
Interventions:   Drug: Pradaxa (dabigatran);   Drug: Vitamin K antagonist
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery

Conditions:   Thoracic Surgery;   Atrial Fibrillation in High Risk Patients
Interventions:   Drug: Amiodarone;   Drug: N-Acetylcysteine;   Drug: Placebo
Sponsors:   Memorial Sloan Kettering Cancer Center;   Washington University School of Medicine;   The Cleveland Clinic;   Vanderbilt University School of Medicine
Recruiting - verified September 2016

Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation

Condition:   Aortic Valve Disorder
Intervention:  
Sponsors:   Institute for Clinical and Experimental Medicine;   Faculty Hospital Kralovske Vinohrady;   General University Hospital, Prague;   VZW Cardiovascular Research Center Aalst
Recruiting - verified September 2016

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Recruiting - verified September 2016

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran;   Drug: Wafrarin
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified September 2016

Patient Convenience Study (RE-SONANCE)

Conditions:   Atrial Fibrillation;   Stroke
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients

Condition:   Vascular Calcification
Interventions:   Drug: rivaroxaban;   Dietary Supplement: Vitamin K2
Sponsor:   Onze Lieve Vrouw Hospital
Recruiting - verified September 2016

PV Cryoablation Efficacy (COR ADVANCE Study)

Condition:   Atrial Fibrillation
Intervention:   Device: ArticFont Advance ST Cryoenergy Balloon Catheter
Sponsor:   Hospital San Carlos, Madrid
Recruiting - verified September 2016

AF Patient Preference Study

Condition:   Atrial Fibrillation
Interventions:   Drug: VKA: Warfarin (Waran);   Drug: NOAC: Rivaroxaban (Xarelto, BAY59-7939);   Drug: NOAC: Dabigatran etexilate;   Drug: NOAC: Apixaban;   Drug: NOAC: Edoxaban;   Drug: NOAC: Lixiana
Sponsor:   Bayer
Recruiting - verified September 2016

Effects of Mindfulness on Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Device: MUSE Headband
Sponsor:   Newmarket Electrophysiology Research Group Inc
Recruiting - verified September 2016

Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel

Condition:   Coronary Artery Disease
Interventions:   Drug: Edoxaban 60 mg;   Drug: Edoxaban 30 mg;   Drug: Clopidogrel 75 mg;   Drug: Aspirin 81 mg
Sponsors:   University of Florida;   Daiichi Sankyo Inc.
Recruiting - verified September 2016

Utilizing a Novel Method to Map Sources of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Procedure: MRI;   Procedure: ECG
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified September 2016

Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ACP-196;   Drug: ibrutinib
Sponsor:   Acerta Pharma BV
Recruiting - verified September 2016

Amplatzer™Amulet™ Post-Market Study

Conditions:   Atrial Fibrillation;   Thromboembolism;   Stroke
Intervention:   Device: Subjects implanted with Amulet Device
Sponsor:   St. Jude Medical
Recruiting - verified July 2016

Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

Condition:   Anticoagulation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Badalona Serveis Assistencial;   IMS Health
Completed - verified September 2016

Canadian Pradaxa Acute Stroke Safety Study

Conditions:   Ischemic Attack, Transient;   Stroke
Intervention:   Drug: Dabigatran
Sponsors:   University of Alberta;   Boehringer Ingelheim
Recruiting - verified September 2016

Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   Medtronic Atrial Fibrillation Solutions;   IHF GmbH - Institut für Herzinfarktforschung
Recruiting - verified September 2016

Left Atrial Volume Index in Asymptomatic Aortic Stenosis

Conditions:   Aortic Valve Stenosis;   Heart Failure
Intervention:  
Sponsor:   Odense University Hospital
Completed - verified September 2016

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified September 2016

Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

Conditions:   Transient Ischemic Attack;   Stroke;   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Warfarin
Sponsors:   University of South Florida;   Bristol-Myers Squibb
Recruiting - verified September 2016

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Phenprocoumon
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

A Study to Determine the Feasibility of Wireless Electrocardiography

Conditions:   Cardiac Rhythm Disturbances Including:;   Atrial Fibrillation;   Premature Atrial and Ventricular Beats;   Conduction Defects;   Normal Sinus Rhythm
Intervention:   Device: Observational ambulatory ECG monitoring
Sponsor:   Peerbridge Health, Inc
Completed - verified September 2016

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Completed - verified June 2016

Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack

Condition:   Ischaemic Stroke
Interventions:   Drug: Allopurinol;   Drug: Placebo
Sponsors:   NHS Greater Glasgow and Clyde;   University of Glasgow
Recruiting - verified September 2016

Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: Educational Intervention
Sponsors:   Duke University;   Bristol-Myers Squibb;   Daiichi Sankyo Inc.;   Boehringer Ingelheim;   Bayer
Active, not recruiting - verified September 2016

AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational

Conditions:   Atrial Fibrillation;   Left Atrial Appendage;   Stroke
Intervention:   Device: Amplatzer Cardiac Plug
Sponsor:   St. Jude Medical
Withdrawn - verified September 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2016

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified September 2016

A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence

Conditions:   Persistent Atrial Fibrillation;   Paroxysmal Atrial Fibrillation;   Hypertension
Interventions:   Device: Renal Artery Ablation;   Device: Cardiac Ablation
Sponsor:   St. Jude Medical
Active, not recruiting - verified September 2016

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Completed - verified September 2016

AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol

Conditions:   Atrial Fibrillation;   Left Atrial Appendage;   Stroke
Intervention:   Device: Amplatzer Cardiac Plug
Sponsor:   St. Jude Medical
Completed - verified September 2016

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa (Dabigatran etexilate mesilate)
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

IntegRAted CarE for Atrial Fibrillation - RACE-4

Condition:   Atrial Fibrillation
Interventions:   Other: Specialized AF Clinic;   Other: Usual Care
Sponsors:   Maastricht University Medical Center;   Stichting Achmea Gezondheidszor;   DSW;   CZ Fonds;   Bayer;   Boehringer Ingelheim;   Bristol-Myers Squibb;   Pfizer;   Daiichi Sankyo Inc.
Recruiting - verified September 2016

Effect of 3 Years of Exercise in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Behavioral: Interval exercise;   Behavioral: Moderate exercise;   Behavioral: Control
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   SINTEF Health Research
Active, not recruiting - verified September 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified September 2016

Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF)

Condition:   Atrial Fibrillation
Interventions:   Procedure: PVI with PVAC gold;   Procedure: PVI with Cooled-RF
Sponsor:   Serge A. Trines
Enrolling by invitation - verified September 2016

An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)

Conditions:   Coronary Artery Bypass Surgery;   Coronary Heart Disease;   Coronary Artery Bypass Grafting;   Cardiopulmonary Bypass;   Ischemic Heart Disease;   Heart Failure, Congestive
Intervention:   Drug: Nesiritide
Sponsor:   Scios, Inc.
Withdrawn - verified July 2011

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points